Provided pharmacokinetic analysis and central lab services for the Phase 3 trial
Managed clinical site specimens and conducted clinical test analyses

GCCL announced on the 5th that it provided pharmacokinetic (PK) analysis and central lab services for the clinical trial of Efe (generic name: efpeglenatide), a domestically developed obesity drug created by Hanmi Pharmaceutical.


Efe is Korea's first glucagon-like peptide-1 (GLP-1) obesity drug developed using domestic technology, with Hanmi Pharmaceutical handling the process from candidate discovery through clinical development and commercialization.

GCCL: "Supports Clinical Trial Analysis for Development of Domestic Obesity Drug 'Efe'" View original image

GCCL participated in the Phase 3 clinical trial of Efe in Korea, providing integrated pharmacokinetic analysis and central lab services. It systematically managed the entire process of collecting, transporting, storing and analyzing specimens gathered from approximately 30 clinical sites across Korea. It also provided key clinical test data, including pharmacokinetic analyses evaluating drug concentrations in the body and how they change over time.



“Building on GCCL's specialized analytical capabilities and quality management system, we will continue to serve as a reliable partner to help innovative research and development achievements by Korean pharmaceutical and biotechnology companies lead to successful commercialization,” said GCCL CEO Jo Gwangu.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing